Non-Alcoholic Steatohepatitis (NASH) Market Forecast to 2028

Report Code : TIPRE00009653 | Region : Global | Industry : Pharmaceuticals | Published Date : 29/Apr/2022
Non-Alcoholic Steatohepatitis (NASH) Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib & Cenicriviroc, and Others), Application (Treatment and Diagnosis), and Sales Channel (Hospital Pharmacy, Online Provider, and Retail Pharmacy)

The non-alcoholic steatohepatitis (NASH) market is projected to reach US$ 24,266.81 million by 2028 from US$ 1,631.92 million in 2021; it is expected to grow at a CAGR of 47.1% from 2021 to 2028.

Major factors driving the non-alcoholic steatohepatitis (NASH) market growth include the rising prevalence of NASH and increasing initiatives for the awareness of NASH. The growing number of clinical trials involving combination studies of drugs are likely to introduce future trends in the market during the forecast period. However, the lack of established guidelines for the diagnosis and management of NASH, and withdrawal of drugs from the marketing authorization stage of clinical trials hamper the non-alcoholic steatohepatitis (NASH) market growth.

NASH is a potentially fatal illness that causes extensive scarring and cirrhosis of the liver. NAFLD is the most common chronic liver disease globally. NASH is a progressive form of NAFLD, which is gradually becoming the major cause of end-stage liver diseases and liver transplantation. According to the data published by the Global Liver Institute, NASH was termed as an epidemic on June 12, 2019. It affects over ~115 million people, and 357 million people are expected to be affected by this condition by 2030. Obesity, type 2 diabetes, and hyperlipidemia are substantial risk factors for NAFLD and NASH; more than ~70% of people are obese, ~75% have type 2 diabetes, and 20–80% have hyperlipidemia worldwide. NASH, if left untreated, can progress to cirrhosis and liver cancer, and raise the need for a liver transplant.

As per the data published by the American Liver Foundation, NAFLD is the most common chronic liver disease in the US. ~25% of adults in the US have been estimated to have NAFLD, of which ~20% have NASH, i.e., 5% of adults in the US. According to the NASH Education Program, NASH prevalence is expected to increase by 63% from 2015 to 2030 and NASH is predicted to become the major cause of liver transplantation in the US during 2020–2025. The American Association for the Study of Liver Diseases published a report in 2018 using Markov modeling to forecast NAFLD disease till 2030. As per the study, the prevalence of NAFLD and NASH cases is expected to increase by 21% and 63%, respectively, resulting in 33.5% and 27% prevalence rates, respectively, in adults.

Despite its increasing prevalence, NAFLD/NASH remains an under-recognized condition, and early detection is critical to reducing the risk of progression and its associated consequences. Thus, the growing prevalence of NASH drives the non-alcoholic steatohepatitis (NASH) market.

The non-alcoholic steatohepatitis (NASH) market, by product, is segmented into vitamin E and pioglitazone, ocaliva, elafibranor, selonsertib & cenicriviroc, and others. In 2021, the others segment held the largest share of the market. The selonsertib & cenicriviroc segment is expected to register the fastest CAGR in the non-alcoholic steatohepatitis (NASH) market during the forecast period.

The non-alcoholic steatohepatitis (NASH) market, based on application, is segmented into treatment and diagnosis. In 2021, the treatment segment held a larger share of the market. However, the treatment segment is expected to register a higher CAGR during the forecast period.

The non-alcoholic steatohepatitis (NASH) market, based on distribution channel, is segmented into hospital pharmacy, retail pharmacy, and online provider. In 2021, the retail pharmacies segment held the largest share of the market. Moreover, it is expected to register the highest CAGR in the non-alcoholic steatohepatitis (NASH) market during 2021–2028.

The Organization for Economic Co-operation and Development (OECD), National Institutes of Health (NIH), National Healthcare Service (NHS), Centers for Disease Control and Prevention (CDC), Diabetes UK, National Center for Biotechnology Information (NCBI), Korean Diabetes Association (KDA), United Nations (UN) Global Population Prospects, National Statistics Institute, and World Health Organization (WHO) are among the major secondary sources referred to while preparing the report on the non-alcoholic steatohepatitis (NASH) market.

List of Companies:

1. Genfit SA

2. One Way Liver, S.L.

3. BioPredictive S.A.S

4. Cadila Pharmaceuticals Ltd.

5. Prometheus Laboratories

6. Siemens Healthineers AG

7. Intercept Pharmaceuticals, Inc.

8. Novartis AG

9. Galmed Pharmaceuticals

10. Laboratory Corporation of America Holdings

TABLE OF CONTENTS

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 Global Non-Alcoholic Steatohepatitis Market – By Product

1.3.2 Global Non-Alcoholic Steatohepatitis Market – By Application

1.3.3 Global Non-Alcoholic Steatohepatitis Market – By Sales Channel

1.3.4 Global Non-Alcoholic Steatohepatitis Market – By Geography

2. Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Non-Alcoholic Steatohepatitis Market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 North America PEST Analysis

4.2.2 Europe PEST Analysis

4.2.3 Asia Pacific PEST Analysis

4.2.4 Middle East And Africa PEST Analysis

4.2.5 South And Central America PEST Analysis

4.3 Experts Opinion

5. Non-alcoholic steatohepatitis (NASH) Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Rising Prevalence of NASH

5.1.2 Increasing Initiatives for the Awareness of NASH

5.2 Market Restraints

5.2.1 Lack of Established Guidelines in the Diagnosis and Management of NASH

5.2.2 Withdrawal of Drugs from Seeking Marketing Authorization for NASH

5.3 Market Opportunities

5.3.1 Growing Opportunities in Developing Nations

5.3.2 High Competition among Market Players to Manufacture the First Marketed NASH Drug Creates Global Sales Opportunity

5.4 Future Trends

5.4.1 Growing Clinical Trials Involving Combination Studies of Drugs

5.5 Impact Analysis

6. Non-alcoholic steatohepatitis (NASH) Market– Global Analysis

6.1 Global Non-Alcoholic Steatohepatitis Market Revenue Forecast and Analysis

6.1.1 Global Non-Alcoholic Steatohepatitis Market Revenue Forecast and Analysis

6.1.2 Global Non-Alcoholic Steatohepatitis Market – Market Potential Analysis, By Region

6.2 Market Positioning Analysis of Key Players in Non-Alcoholic Steatohepatitis Market

6.2.1 Company Analysis

6.2.2 Growth Strategy Analysis

6.2.3 Performance of Key Players

6.2.3.1 Intercept Pharmaceuticals, Inc.

6.2.3.2 Galmed Pharmaceuticals, Inc.

7. Global Non-alcoholic steatohepatitis (NASH) Market Revenue and Forecasts To 2028– by Product

7.1 Overview

7.2 Product Market Revenue and Forecast Analysis (US$ Mn)

7.3 Vitamin E and Pioglitazone

7.3.1 Overview

7.3.2 Vitamin E and Pioglitazone Revenue and Forecast to 2028 (US$ Mn)

7.4 Ocaliva

7.4.1 Overview

7.4.2 Ocaliva Revenue and Forecast to 2028 (US$ Mn)

7.5 Elafibranor

7.5.1 Overview

7.5.2 Elafibranor Revenue and Forecast to 2028 (US$ Mn)

7.6 Selonsertib & Cenicriviroc

7.6.1 Overview

7.6.2 Selonsertib Revenue and Forecast to 2028 (US$ Mn)

7.7 Others

7.7.1 Overview

7.7.2 Others Revenue and Forecast to 2028 (US$ Mn)

8. Global Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Forecast to 2028 – by Application

8.1 Overview

8.2 Application Market Revenue and Forecast Analysis (US$ Mn)

8.3 Treatment

8.3.1 Overview

8.3.2 Treatment Market Revenue and Forecast to 2028 (US$ Mn)

8.4 Diagnosis

8.4.1 Overview

8.4.2 Diagnosis Market Revenue and Forecast to 2028 (US$ Mn)

9. Global Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Forecast to 2028 – by Sales Channel

9.1 Overview

9.2 Sales Channel Market Revenue and Forecast Analysis (US$ Mn)

9.3 Hospital Pharmacy

9.3.1 Overview

9.3.2 Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

9.4 Retail Pharmacy

9.4.1 Overview

9.4.2 Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

9.5 Online Provider

9.5.1 Overview

9.5.2 Online Provider Market Revenue and Forecast to 2028 (US$ Mn)

10. Non-alcoholic steatohepatitis (NASH) Market Revenue and Forecasts to 2028 – Geographical Analysis

10.1 North America: Non-Alcoholic Steatohepatitis Market

10.1.1 Overview

10.1.2 North America: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)

10.1.3 North America: Non-Alcoholic Steatohepatitis Market, by Product, 2019–2028 (US$ Million)

10.1.4 North America: Non-Alcoholic Steatohepatitis Market, by Application, 2019–2028 (US$ Million)

10.1.5 North America: Non-Alcoholic Steatohepatitis Market, by Sales Channel, 2019–2028 (US$ Million)

10.1.6 North America: Non-Alcoholic Steatohepatitis Market, by Country, 2021 & 2028 (%)

10.1.6.1 US: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)

10.1.6.1.1 US: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)

10.1.6.1.2 US: Non-Alcoholic Steatohepatitis Market, by Product, 2019–2028 (US$ Million)

10.1.6.1.3 US: Non-Alcoholic Steatohepatitis Market, by Application, 2019–2028 (US$ Million)

10.1.6.1.4 US: Non-Alcoholic Steatohepatitis Market, by Sales Channel, 2019–2028 (US$ Million)

10.1.6.2 Canada: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)

10.1.6.2.1 Canada: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)

10.1.6.2.2 Canada: Non-Alcoholic Steatohepatitis Market, by Product, 2019–2028 (US$ Million)

10.1.6.2.3 Canada: Non-Alcoholic Steatohepatitis Market, by Application, 2019–2028 (US$ Million)

10.1.6.2.4 Canada: Non-Alcoholic Steatohepatitis Market, by Sales Channel, 2019–2028 (US$ Million)

10.1.6.3 Mexico: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)

10.1.6.3.1 Mexico: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)

10.1.6.3.2 Mexico: Non-Alcoholic Steatohepatitis Market, by Product, 2019–2028 (US$ Million)

10.1.6.3.3 Mexico: Non-Alcoholic Steatohepatitis Market, by Application, 2019–2028 (US$ Million)

10.1.6.3.4 Mexico: Non-Alcoholic Steatohepatitis Market, by Sales Channel, 2019–2028 (US$ Million)

10.2 Europe: Non-alcoholic steatohepatitis (NASH) Market

10.2.1 Overview

10.2.2 Europe: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.2.3 Europe: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

10.2.4 Europe: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

10.2.5 Europe: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

10.2.6 Europe: Non-alcoholic steatohepatitis (NASH) Market, by Country, 2021 & 2028 (%)

10.2.6.1 Germany: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.1.1 Overview

10.2.6.1.2 Germany: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.1.3 Germany: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

10.2.6.1.4 Germany: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

10.2.6.1.5 Germany: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

10.2.6.2 France: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.2.1 Overview

10.2.6.2.2 France: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.2.3 France: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

10.2.6.2.4 France: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

10.2.6.2.5 France: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

10.2.6.3 UK: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.3.1 Overview

10.2.6.3.2 UK: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.3.3 UK: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

10.2.6.3.4 UK: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

10.2.6.3.5 UK: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

10.2.6.4 Italy: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.4.1 Overview

10.2.6.4.2 Italy: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.4.3 Italy: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

10.2.6.4.4 Italy: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

10.2.6.4.5 Italy: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

10.2.6.5 Spain: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.5.1 Overview

10.2.6.5.2 Spain: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.5.3 Spain: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

10.2.6.5.4 Spain: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

10.2.6.5.5 Spain: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

10.2.6.6 Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.6.1 Overview

10.2.6.6.2 Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.6.3 Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

10.2.6.6.4 Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

10.2.6.6.5 Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

10.3 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecasts To 2028

10.3.1 Overview

10.3.2 Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market - Revenue and Forecast to 2028 (USD Million)

10.3.3 Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, By Product, 2019–2028 (USD Million)

10.3.4 Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, By Application, 2019–2028 (USD Million)

10.3.5 Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel, 2019–2028 (USD Million)

10.3.6 Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, by Country, 2021 & 2028 (%)

10.3.6.1 China: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.3.6.1.1 China: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.3.6.1.2 China: Non-Alcoholic Steatohepatitis (NASH) Market, By Product, 2019–2028 (USD Million)

10.3.6.1.3 China: Non-Alcoholic Steatohepatitis (NASH) Market, By Application, 2019–2028 (USD Million)

10.3.6.1.4 China: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel, 2019–2028 (USD Million)

10.3.6.2 Japan: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.3.6.2.1 Japan: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.3.6.2.2 Japan: Non-Alcoholic Steatohepatitis (NASH) Market, By Product, 2019–2028 (USD Million)

10.3.6.2.3 Japan: Non-Alcoholic Steatohepatitis (NASH) Market, By Application, 2019–2028 (USD Million)

10.3.6.2.4 Japan: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel, 2019–2028 (USD Million)

10.3.6.3 India: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.3.6.3.1 India: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.3.6.3.2 India: Non-Alcoholic Steatohepatitis (NASH) Market, By Product, 2019–2028 (USD Million)

10.3.6.3.3 India: Non-Alcoholic Steatohepatitis (NASH) Market, By Application, 2019–2028 (USD Million)

10.3.6.3.4 India: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel, 2019–2028 (USD Million)

10.3.6.4 Australia: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.3.6.4.1 Australia: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.3.6.4.2 Australia: Non-Alcoholic Steatohepatitis (NASH) Market, By Product, 2019–2028 (USD Million)

10.3.6.4.3 Australia: Non-Alcoholic Steatohepatitis (NASH) Market, By Application, 2019–2028 (USD Million)

10.3.6.4.4 Australia: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel, 2019–2028 (USD Million)

10.3.6.5 South Korea: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.3.6.5.1 South Korea: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.3.6.5.2 South Korea: Non-Alcoholic Steatohepatitis (NASH) Market, By Product, 2019–2028 (USD Million)

10.3.6.5.3 South Korea: Non-Alcoholic Steatohepatitis (NASH) Market, By Application, 2019–2028 (USD Million)

10.3.6.5.4 South Korea: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel, 2019–2028 (USD Million)

10.3.6.6 Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.3.6.6.1 Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)

10.3.6.6.2 Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, By Product, 2019–2028 (USD Million)

10.3.6.6.3 Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, By Application, 2019–2028 (USD Million)

10.3.6.6.4 Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel, 2019–2028 (USD Million)

10.4 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Market

10.4.1 Overview

10.4.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

10.4.3 Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, by Product (US$ Million)

10.4.4 Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, by Application (US$ Million)

10.4.5 Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel– Revenue and Forecast to 2028 (US$ Million)

10.4.6 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, by Country (%)

10.4.6.1 UAE: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

10.4.6.1.1 UAE: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

10.4.6.1.2 UAE: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Product (US$ Million)

10.4.6.1.3 UAE: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast To 2028, By Application (US$ Million)

10.4.6.1.4 UAE: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel– Revenue and Forecast to 2028 (US$ Million)

10.4.6.2 Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

10.4.6.2.1 Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

10.4.6.2.2 Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Product (US$ Million)

10.4.6.2.3 Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast To 2028, By Application (US$ Million)

10.4.6.2.4 Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel– Revenue and Forecast to 2028 (US$ Million)

10.4.6.3 South Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

10.4.6.3.1 South Africa Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

10.4.6.3.2 South Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Product (US$ Million)

10.4.6.3.3 South Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast To 2028, By Application (US$ Million)

10.4.6.3.4 South Africa: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

10.4.6.4 Rest of Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

10.4.6.4.1 Rest of Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

10.4.6.4.2 Rest of Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Product (US$ Million)

10.4.6.4.3 Rest of Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast To 2028, By Application (US$ Million)

10.4.6.4.4 Rest of Middle East & Africa: D Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

10.5 South and Central America Non-Alcoholic Steatohepatitis Market Revenue and Forecast To 2028

10.5.1 Overview

10.5.2 South and Central America: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)

10.5.3 South and Central America: Non-Alcoholic Steatohepatitis Market , by Product, 2019–2028 (USD Million)

10.5.4 South and Central America: Non-Alcoholic Steatohepatitis Market, by Application, 2019–2028 (USD Million)

10.5.5 South and Central America: Non-Alcoholic Steatohepatitis Market, by Sales Channel, 2019–2028 (USD Million)

10.5.6 South and Central America: Non-Alcoholic Steatohepatitis Market, by Country, 2021 & 2028 (%)

10.5.6.1 Brazil: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)

10.5.6.1.1 Brazil: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)

10.5.6.1.2 Brazil: Non-Alcoholic Steatohepatitis Market , by Product, 2019–2028 (USD Million)

10.5.6.1.3 Brazil: Non-Alcoholic Steatohepatitis Market, by Application, 2019–2028 (USD Million)

10.5.6.1.4 Brazil: Non-Alcoholic Steatohepatitis Market, by Sales Channel, 2019–2028 (USD Million)

10.5.6.2 Argentina: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)

10.5.6.2.1 Argentina: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)

10.5.6.2.2 Argentina: Non-Alcoholic Steatohepatitis Market , by Product, 2019–2028 (USD Million)

10.5.6.2.3 Argentina: Non-Alcoholic Steatohepatitis Market , by Application, 2019–2028 (USD Million)

10.5.6.2.4 Argentina: Non-Alcoholic Steatohepatitis Market, by Sales Channel, 2019–2028 (USD Million)

10.5.6.3 Rest of South and Central America: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)

10.5.6.3.1 Rest of South and Central America: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)

10.5.6.3.2 Rest of South and Central America: Non-Alcoholic Steatohepatitis Market , by Product, 2019–2028 (USD Million)

10.5.6.3.3 Rest of South and Central America: Non-Alcoholic Steatohepatitis Market , by Application, 2019–2028 (USD Million)

10.5.6.3.4 Rest of South and Central America: Non-Alcoholic Steatohepatitis Market , by Sales Channel, 2019–2028 (USD Million)

11. Impact Of COVID-19 Pandemic on Non-alcoholic steatohepatitis (NASH) Market

11.1 North America: Impact Assessment of COVID-19 Pandemic

11.2 Europe: Impact Assessment of COVID-19 Pandemic

11.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic

11.4 Middle East & Africa: Impact Assessment of COVID-19 Pandemic

11.5 South and Central America: Impact Assessment of COVID-19 Pandemic

12. Non-alcoholic steatohepatitis (NASH) Market–Industry Landscape

12.1 Overview

12.2 Growth Strategies in the Non-Alcoholic Steatohepatitis Market

12.3 Organic Developments

12.3.1 Overview

12.4 Inorganic Developments

12.4.1 Overview

13. Company Profiles

13.1 Cadila Pharmaceuticals Ltd.

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

13.2 Intercept Pharmaceuticals, Inc

13.2.1 Key Facts

13.2.2 Business Description

13.2.3 Products and Services

13.2.4 Financial Overview

13.2.5 SWOT Analysis

13.2.6 Key Developments

13.3 Novartis AG

13.3.1 Key Facts

13.3.2 Business Description

13.3.3 Products and Services

13.3.4 Financial Overview

13.3.5 SWOT Analysis

13.3.6 Key Developments

13.4 Galmed Pharmaceuticals.

13.4.1 Key Facts

13.4.2 Business Description

13.4.3 Products and Services

13.4.4 Financial Overview

13.4.5 SWOT Analysis

13.4.6 Key Developments

13.5 GENFIT.

13.5.1 Key Facts

13.5.2 Business Description

13.5.3 Products and Services

13.5.4 Financial Overview

13.5.5 SWOT Analysis

13.5.6 Key Developments

13.6 ONE WAY LIVER, S.L

13.6.1 Key Facts

13.6.2 Business Description

13.6.3 Products and Services

13.6.4 Financial Overview

13.6.5 SWOT Analysis

13.6.6 Key Developments

13.7 BioPredictive S.A.S

13.7.1 Key Facts

13.7.2 Business Description

13.7.3 Products and Services

13.7.4 Financial Overview

13.7.5 SWOT Analysis

13.7.6 Key Developments

13.8 Prometheus Laboratories

13.8.1 Key Facts

13.8.2 Business Description

13.8.3 Products and Services

13.8.4 Financial Overview

13.8.5 SWOT Analysis

13.8.6 Key Developments

13.9 Siemens Healthineers AG

13.9.1 Key Facts

13.9.2 Business Description

13.9.3 Products and Services

13.9.4 Financial Overview

13.9.5 SWOT Analysis

13.9.6 Key Developments

13.10 Laboratory Corporation of America Holdings

13.10.1 Key Facts

13.10.2 Business Description

13.10.3 Products and Services

13.10.4 Financial Overview

13.10.5 SWOT Analysis

13.10.6 Key Developments

14. Appendix

14.1 About The Insight Partners

14.2 Glossary of Terms

LIST OF TABLES.

Table 1. Discontinued Drugs and Companies

Table 2. Drug, Phase, and Company

Table 3. North America Non-Alcoholic Steatohepatitis Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 4. North America Non-Alcoholic Steatohepatitis Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 5. North America Non-Alcoholic Steatohepatitis Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 6. US Non-Alcoholic Steatohepatitis Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 7. US Non-Alcoholic Steatohepatitis Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 8. US Non-Alcoholic Steatohepatitis Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 9. Canada: Non-Alcoholic Steatohepatitis Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 10. Canada Non-Alcoholic Steatohepatitis Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 11. Canada Non-Alcoholic Steatohepatitis Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 12. Mexico: Non-Alcoholic Steatohepatitis Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 13. Mexico Non-Alcoholic Steatohepatitis Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 14. Mexico Non-Alcoholic Steatohepatitis Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 15. Europe: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 16. Europe: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 17. Europe: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 18. Germany: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 19. Germany: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 20. Germany: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 21. France: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 22. France: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 23. France: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 24. UK: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 25. UK: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 26. UK: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 27. Italy: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 28. Italy: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 29. Italy: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 30. Spain: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 31. Spain: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 32. Spain: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 33. Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 34. Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 35. Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 36. Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, By Product – Revenue and Forecast to 2028 (USD Million)

Table 37. Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, By Application – Revenue and Forecast to 2028 (USD Million)

Table 38. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (USD Million)

Table 39. China: Non-Alcoholic Steatohepatitis (NASH) Market, By Product – Revenue and Forecast to 2028 (USD Million)

Table 40. China: Non-Alcoholic Steatohepatitis (NASH) Market, By Application – Revenue and Forecast to 2028 (USD Million)

Table 41. China: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (USD Million)

Table 42. Japan: Non-Alcoholic Steatohepatitis (NASH) Market, By Product – Revenue and Forecast to 2028 (USD Million)

Table 43. Japan: Non-Alcoholic Steatohepatitis (NASH) Market, By Application – Revenue and Forecast to 2028 (USD Million)

Table 44. Japan: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (USD Million)

Table 45. India: Non-Alcoholic Steatohepatitis (NASH) Market, By Product – Revenue and Forecast to 2028 (USD Million)

Table 46. India: Non-Alcoholic Steatohepatitis (NASH) Market, By Application – Revenue and Forecast to 2028 (USD Million)

Table 47. India: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (USD Million)

Table 48. Australia: Non-Alcoholic Steatohepatitis (NASH) Market, By Product – Revenue and Forecast to 2028 (USD Million)

Table 49. Australia: Non-Alcoholic Steatohepatitis (NASH) Market, By Application – Revenue and Forecast to 2028 (USD Million)

Table 50. Australia: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (USD Million)

Table 51. South Korea: Non-Alcoholic Steatohepatitis (NASH) Market, By Product – Revenue and Forecast to 2028 (USD Million)

Table 52. South Korea: Non-Alcoholic Steatohepatitis (NASH) Market, By Application – Revenue and Forecast to 2028 (USD Million)

Table 53. South Korea: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (USD Million)

Table 54. Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, By Product – Revenue and Forecast to 2028 (USD Million)

Table 55. Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, By Application – Revenue and Forecast to 2028 (USD Million)

Table 56. Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (USD Million)

Table 57. Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, by Product (US$ Million)

Table 58. Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, by Application (US$ Million)

Table 59. Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel– Revenue and Forecast to 2028 (US$ Million)

Table 60. UAE: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Product (US$ Million)

Table 61. UAE: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Application (US$ Million)

Table 62. UAE: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel– Revenue and Forecast to 2028 (US$ Million)

Table 63. Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Product (US$ Million)

Table 64. Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Application (US$ Million)

Table 65. Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel– Revenue and Forecast to 2028 (US$ Million)

Table 66. South Africa Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Product (US$ Million)

Table 67. South Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Application (US$ Million)

Table 68. South Africa: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 69. Rest of Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Product (US$ Million)

Table 70. Rest of Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Application (US$ Million)

Table 71. Rest of Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 72. South and Central America: Non-Alcoholic Steatohepatitis Market , by Product – Revenue and Forecast to 2028 (USD Million)

Table 73. South and Central America: Non-Alcoholic Steatohepatitis Market, by Application– Revenue and Forecast to 2028 (USD Million)

Table 74. South and Central America: Non-Alcoholic Steatohepatitis Market, by Sales Channel– Revenue and Forecast to 2028 (USD Million)

Table 75. Brazil: Non-Alcoholic Steatohepatitis Market , by Product – Revenue and Forecast to 2028 (USD Million)

Table 76. Brazil: Non-Alcoholic Steatohepatitis Market, by Application– Revenue and Forecast to 2028 (USD Million)

Table 77. Brazil: Non-Alcoholic Steatohepatitis Market, by Sales Channel– Revenue and Forecast to 2028 (USD Million)

Table 78. Argentina: Non-Alcoholic Steatohepatitis Market , by Product – Revenue and Forecast to 2028 (USD Million)

Table 79. Argentina: Non-Alcoholic Steatohepatitis Market , by Application– Revenue and Forecast to 2028 (USD Million)

Table 80. Argentina: Non-Alcoholic Steatohepatitis Market , by Sales Channel– Revenue and Forecast to 2028 (USD Million)

Table 81. Rest of South and Central America: Non-Alcoholic Steatohepatitis Market , by Product – Revenue and Forecast to 2028 (USD Million)

Table 82. Rest of South and Central America: Non-Alcoholic Steatohepatitis Market , by Application– Revenue and Forecast to 2028 (USD Million)

Table 83. Rest of South and Central America: Non-Alcoholic Steatohepatitis Market , by Sales Channel– Revenue and Forecast to 2028 (USD Million)

Table 84. Organic Developments Done By Companies

Table 85. Inorganic Developments Done By Companies

Table 86. Glossary of Terms

List of Companies:

1. Genfit SA

2. One Way Liver, S.L.

3. BioPredictive S.A.S

4. Cadila Pharmaceuticals Ltd.

5. Prometheus Laboratories

6. Siemens Healthineers AG

7. Intercept Pharmaceuticals, Inc.

8. Novartis AG

9. Galmed Pharmaceuticals

10. Laboratory Corporation of America Holdings

Reason To Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Non-Alcoholic Steatohepatitis market.

• Highlights key business priorities in order to assist companies to realign their business strategies.

• The key findings and recommendations highlight crucial progressive industry trends in the global Non-Alcoholic Steatohepatitis market, thereby allowing players across the value chain to develop effective long-term strategies.

• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

• Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution

AVAILABLE CUSTOMIZATION RESEARCH METHODOLOGY REQUEST FOR TOC FREE SAMPLE REPORT
CHOOSE LICENCE TYPE
(Non-Alcoholic Steatohepatitis (NASH) Market Forecast to 2028 )
  • Single User Price $4,550$3,640
  • Site Price $6,550$5,240
  • Enterprise Price $8,550$6,840
Buy Now Add to Cart
REQUEST FOR TOC
SPEAK TO ANALYST
FREE SAMPLE
REPORT
INQUIRE BEFORE
BUYING
TOP
Quick Enquiry